CTNM vs KYMR vs IMVT vs ARQT vs ABBV

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). AbbVie Inc. (ABBV) offers the better valuation at 96. 1x trailing P/E (16. 0x forward), making it the more compelling value choice. Analysts rate Contineum Therapeutics, Inc. Class A Common Stock (CTNM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, AbbVie Inc.

is actually cheaper at 16. 0x.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +213. 0%, compared to -22. 9% for Contineum Therapeutics, Inc. Class A Common Stock (CTNM). Over 10 years, the gap is even starker: ABBV returned +362. 2% versus CTNM's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus Immunovant, Inc. 's 1. 66β — meaning IMVT is approximately 1118% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -33. 1% for Contineum Therapeutics, Inc. Class A Common Stock. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 16. 0x forward P/E versus 122. 5x for Arcutis Biotherapeutics, Inc. — 106. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARQT: 39. 5% to $34. 00.

In this comparison, ABBV (2.

9% yield) pays a dividend. CTNM, KYMR, IMVT, ARQT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Immunovant, Inc. (IMVT) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +362. 2%, IMVT: +237. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTNM is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; ABBV is a large-cap quality compounder stock. ABBV pays a dividend while CTNM, KYMR, IMVT, ARQT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.